Drug Profile
Cordycepin - OncoVista Innovative Therapies
Alternative Names: 3'-deoxyadenosine; OVI-123Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator OXiGENE
- Developer OncoVista Innovative Therapies
- Class Amines; Antifungals; Antineoplastics; Nucleosides; Purines; Small molecules
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Leukaemia
Most Recent Events
- 13 Sep 2017 No recent reports on development identified - Preclinical for Leukaemia in France (IV)
- 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
- 01 Apr 2013 Preclinical development is ongoing in France. Phase I/II trial is still on hold until additional funding is available.